Showing results (111-120 of 140) with videos related to
Sort By:
Pageof 14
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 29, 2024
Final Results From the Randomized Phase III ASCENT Clinical Trial in Metastatic Triple-Negative Breast Cancer and Association of Outcomes by Human Epidermal Growth Factor Receptor 2 and Trophoblast Cell Surface Antigen 2 ExpressionAditya Bardia, Hope S Rugo, Sara M Tolaney, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 21, 2018
Paclitaxel With Inhibitor of Apoptosis Antagonist, LCL161, for Localized Triple-Negative Breast Cancer, Prospectively Stratified by Gene Signature in a Biomarker-Driven Neoadjuvant TrialAditya Bardia, Marina Parton, Sherko Kümmel, et al.The Journal of Biological Chemistry|December 4, 2014
Estrogen receptor (ER)α-regulated lipocalin 2 expression in adipose tissue links obesity with breast cancer progressionBrian G Drew, Habib Hamidi, Zhenqi Zhou, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 4, 2019
Neoadjuvant Trastuzumab Emtansine and Pertuzumab in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Three-Year Outcomes From the Phase III KRISTINE StudySara A Hurvitz, Miguel Martin, Kyung Hae Jung, et al.Breast (Edinburgh, Scotland)|March 10, 2015
Trebananib (AMG 386) plus weekly paclitaxel with or without bevacizumab as first-line therapy for HER2-negative locally recurrent or metastatic breast cancer: A phase 2 randomized studyVéronique Diéras, Hans Wildiers, Jacek Jassem, et al.The Oncologist|May 24, 2021
Efficacy of Neratinib Plus Capecitabine in the Subgroup of Patients with Central Nervous System Involvement from the NALA TrialSara A Hurvitz, Cristina Saura, Mafalda Oliveira, et al.Journal for Immunotherapy of Cancer|July 29, 2020
Globo H-KLH vaccine adagloxad simolenin (OBI-822)/OBI-821 in patients with metastatic breast cancer: phase II randomized, placebo-controlled studyChiun-Sheng Huang, Alice L Yu, Ling-Ming Tseng, et al.Breast (Edinburgh, Scotland)|January 26, 2023
Final findings from the CONTROL trial: Strategies to reduce the incidence and severity of neratinib-associated diarrhea in patients with HER2-positive early-stage breast cancerArlene Chan, Manuel Ruiz-Borrego, Gavin Marx, et al.JAMA Oncology|September 25, 2025
Ribociclib Plus Endocrine Therapy in Hormone Receptor-Positive/ERBB2-Negative Early Breast Cancer: 4-Year Outcomes From the NATALEE Randomized Clinical TrialPeter A Fasching, Daniil Stroyakovskiy, Denise A Yardley, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 18, 2024
Abemaciclib Plus Fulvestrant in Advanced Breast Cancer After Progression on CDK4/6 Inhibition: Results From the Phase III postMONARCH TrialKevin Kalinsky, Giampaolo Bianchini, Erika Hamilton, et al.Pageof 14